Seizert Capital Partners LLC Buys 21,065 Shares of Pfizer Inc. $PFE

Seizert Capital Partners LLC grew its holdings in Pfizer Inc. (NYSE:PFE) by 17.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 143,297 shares of the biopharmaceutical company’s stock after purchasing an additional 21,065 shares during the period. Seizert Capital Partners LLC’s holdings in Pfizer were worth $3,651,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PFE. Norges Bank purchased a new position in shares of Pfizer during the 2nd quarter worth $2,270,157,000. Vanguard Group Inc. lifted its holdings in shares of Pfizer by 1.9% in the second quarter. Vanguard Group Inc. now owns 533,363,457 shares of the biopharmaceutical company’s stock worth $12,928,730,000 after buying an additional 10,198,330 shares in the last quarter. Arrowstreet Capital Limited Partnership boosted its holdings in shares of Pfizer by 43.4% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 18,718,955 shares of the biopharmaceutical company’s stock valued at $453,747,000 after purchasing an additional 5,662,309 shares during the last quarter. Assenagon Asset Management S.A. increased its holdings in shares of Pfizer by 75.0% in the third quarter. Assenagon Asset Management S.A. now owns 8,689,103 shares of the biopharmaceutical company’s stock worth $221,398,000 after purchasing an additional 3,722,531 shares during the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in shares of Pfizer by 84.9% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 7,561,946 shares of the biopharmaceutical company’s stock worth $183,302,000 after acquiring an additional 3,472,240 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on PFE shares. Bank of America reduced their target price on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a report on Monday, December 15th. Wolfe Research set a $24.00 price target on shares of Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. Wall Street Zen downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. Citigroup assumed coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 price target on the stock. Finally, Scotiabank started coverage on Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $27.88.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer secured a license to use Novavax’s Matrix‑M adjuvant for vaccine development, which could accelerate and broaden Pfizer’s infectious‑disease vaccine programs and reduce development risk/costs — a clear pipeline positive. Novavax enters license agreement with Pfizer for vaccine development Novavax stock rises after licensing Matrix-M adjuvant to Pfizer
• Neutral Sentiment: Analysts and investors are reassessing Pfizer’s valuation and recent shareholder‑return programs; this discussion can create short‑term volatility as the market re‑prices future cash flows versus buybacks/dividends. Pfizer (PFE) Valuation Check As Investors Reassess Recent Shareholder Returns
• Neutral Sentiment: Q4/near‑term expectations center on continued Eliquis growth offset by softer COVID‑19 sales and steady demand for other non‑oncology drugs; upcoming results/guidance will matter for near‑term sentiment. What to Expect From Pfizer’s Non-Oncology Business in Q4?
• Neutral Sentiment: Thematic ETF coverage of weight‑loss/GLP‑1 exposure mentions Pfizer in broader healthcare context; that’s background noise unless Pfizer announces a direct GLP‑1 play. Ozempic, Mounjaro, Wegovy, or Zepound? This ETF Holds Them All (PFE)
• Negative Sentiment: Pfizer is restructuring its holdings in the ViiV HIV joint venture (Pfizer exiting; Shionogi increasing stake), which reduces Pfizer’s future exposure to a durable HIV revenue stream — potential long‑term revenue headwind. Shionogi Boosts Stake in ViiV Healthcare as Pfizer Exits Joint HIV Venture
• Negative Sentiment: Commentary noting Pfizer’s multi‑year share decline (consumer pieces on “down 55%”) highlights investor worry about patent cliffs and recent drug setbacks; that narrative can add selling pressure absent fresh positive data or clearer guidance. Down 55%, Should You Buy the Dip on Pfizer?

Pfizer Price Performance

Shares of PFE stock opened at $25.37 on Tuesday. Pfizer Inc. has a fifty-two week low of $20.92 and a fifty-two week high of $27.69. The stock’s 50-day simple moving average is $25.38 and its 200-day simple moving average is $24.99. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.97 and a current ratio of 1.28. The firm has a market capitalization of $144.23 billion, a price-to-earnings ratio of 14.79 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.79 by $0.08. The firm had revenue of $16.65 billion during the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer had a return on equity of 20.17% and a net margin of 15.65%.Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer’s dividend payout ratio is 100.00%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.